Bangalore February 15, 2014:- Hyderabad-based biopharmaceutical company Suven Life Sciences Ltd (Suven) secured two product patents from New Zealand corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2029 and 2030 respectively. The granted patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.
With the new patents, Suven has a total of 19 patents from New Zealand. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.- Business Standard
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…